Publications by authors named "F Acker"

Claim this Profile
R
Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA.
F Acker, M Rost, M Sebastian, A Cortellini

Ann Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.
Friederike C Althoff, Fabian Acker, Sebastian Koschade, Sophie Heinzen, Lukas Aguinarte

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study Group.
Christina Rautenberg, Matthias Stelljes, Gesine Bug, Udo Holtick, Edgar Jost, Fabian Acker

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Fabian Acker

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Activity Relationship Guided Scaffold Hopping Resulted in the Identification of GLPG4970, a Highly Potent Dual SIK2/SIK3 Inhibitor.
Hans Kelgtermans, Maxim De Wachter, Stijn Heyndrickx, Sandy El Bkassiny, Tatiana Lacarriere, Frederique Van Acker

J Med Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis